Athira Pharma Inc (ATHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Athira Pharma Inc (ATHA) has a cash flow conversion efficiency ratio of -0.698x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.40 Million) by net assets ($27.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Athira Pharma Inc (ATHA) net asset quality to measure how much of total assets are equity-financed.
Athira Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore long-term investment intensity of Athira Pharma Inc to see how much of total assets are deployed in long-term investments.
Athira Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athira Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sangsin Brake
KO:041650
|
-0.048x |
|
VisDynamics Holdings Bhd
KLSE:0120
|
0.003x |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
-0.522x |
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
0.015x |
|
Korea Circuit Co Ltd
KO:007815
|
0.038x |
|
Davolink Inc.
KQ:340360
|
0.072x |
|
Worth Peripherals Limited
NSE:WORTH
|
0.067x |
|
Podium Minerals Ltd
AU:POD
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Athira Pharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Athira Pharma Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ATHA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more